RDHL Stock Catalyst: RedHill Biopharma Receives FDA Guidance on RHB-204 Crohn's Disease Program

RedHill Biopharma Ltd. (Nasdaq: RDHL) received guidance from the U.S. Food and Drug Administration (FDA) on the approval path for its RHB-204 Crohn's Disease Program following a Type C meeting. The meeting aimed to discuss the regulatory requirements and development plan for RHB-204, a treatment candidate for nontuberculous mycobacteria (NTM) infections, which are often associated with Crohn's Disease.

The FDA provided specific recommendations on the design and conduct of the pivotal Phase 3 trial, including endpoints, patient population, and trial duration. RedHill Biopharma will use this guidance to refine its clinical development strategy for RHB-204.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.